Johnson & Johnson (JNJ) operating KPIs
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)
Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%
Johnson & Johnson other Cardiovascular sub-franchise — Worldwide sales ($M) ($M)
Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule
Latest, Q3 2026
81
Period ended Sep 30, 2026
Change on a year earlier
-14.7%
95 in Q3 2025
History
19 quarters
Since Q1 2022
Sources
14
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up other cardiovascular sub-franchise — worldwide sales ($m)
- Other Cardiovascular sub-franchise — U.S. sales ($M)31 · Q3 2026
- Other Cardiovascular sub-franchise — International sales ($M)50 · Q3 2026
- Other Cardiovascular sub-franchise — Worldwide reported growth YoY (%)-13.9% · Q3 2026
- Other Cardiovascular sub-franchise — Worldwide operational (constant-currency) growth YoY (%)-14.7% · Q3 2026
Cite this data
StockData. (2026). Johnson & Johnson Other Cardiovascular sub-franchise — Worldwide sales ($M) ($M), quarterly Q1 2022–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/mt_other_cv
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.